Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
October 11, 2022
On October 7-8th, 2022 the 14th edition of the “New developments in interventional cardiology” congress took place in Augustow (Poland), during which Hemolens Diagnostics presented its cutting-edge diagnostic platform – Cardiolens FFR-CT Pro®.
The “New developments in interventional cardiology” is a unique opportunity to learn about the latest trends and breakthroughs in interventional cardiology. During the conference, the most outstanding interventional cardiologists from all over Poland shared their knowledge and experience.
The “New developments in interventional cardiology” conference is organized by the Department of Invasive Cardiology at the University Clinical Hospital in Bialystok and the Podlasie Cardiovascular Centre in Augustow. This event annually brings together more than 300 cardiologists from all over Poland. During this year’s edition participants were able to attend more than 30 lectures and panel discussions on interventional cardiology in its broadest sense.
Also this year, European MedTech company – Hemolens Diagnostics, presented a unique diagnostic solution – a platform for non-invasive diagnostics of coronary artery disease. This was the first time interventional cardiologists could use actual patient data to measure virtual FFR (FFR-CT) with the diagnostic – Cardiolens FR-CT Pro®. The diagnostic solution provided by Hemolens Diagnostics can help cardiologists carry out an accurate and precise anatomical and functional assessment of the coronary arteries in an outpatient way. This ground-breaking platform can make a real difference in reducing the number of invasive procedures and reducing the risk to the patient.
Intended Use:
Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.